Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Gan & Lee Awarded US Fast Track Status for Glioblastoma Treatment

publication date: Jan 29, 2021

Gan & Lee Pharma of Beijing announced its lead oncology candidate was granted US Fast Track Designation for glioblastoma. GLR2007 is a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor. Gan & Lee, which raised $360 million in a Shanghai IPO last year, is known as the first China biopharma to develop biosynthetic human insulin products, with five recombinant insulin analogs currently commercialized in China. Gan & Lee has announced its intention to move beyond diabetes into developing products for oncology, cardiovascular and metabolic diseases. More details....

Stock Symbol: (SHA: 603087)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.